Skin Cancer & Melanoma

Researchers looked at whether time to first distant recurrence of metastatic melanoma was linked to survival outcomes.

The American Cancer Society's Cancer Facts & Figures 2019 report summarized the rate of melanoma over the past 30 years, mortality, and incidence based on sex and ethnicity.

The study authors evaluated the disease-free survival rate among patients with high-risk primary melanoma and the role of routine sentinel lymph node biopsy.

A new study reported that elderly patients experience a different extent of metastatic disease than do adults diagnosed at younger ages.

The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers.

Researchers evaluated the response of patients with BCC to fractionated photodynamic therapy at 30 days after treatment.

In this patient-reported outcomes analysis of the COMBI-AD study, researchers looked at the health-related quality of life in those with resected stage III melanoma with BRAF mutations.

Researchers looked at the outcomes of patients who experienced cutaneous toxic effects after treatment with anti–PD-1 therapy for advanced melanoma compared with patients who did not.

This review summarizes the current available treatment strategies for patients with advanced melanoma when PD-1–directed therapy is not enough.

Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma.

The association between the presence of several viruses and non-melanoma skin cancer was investigated in a recent study.

Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.

A review published in Experimental Dermatology examined the safety and efficacy of nicotinamide in reducing non-melanoma skin cancers.

Survival rates in patients with cSCC receiving high-dose chemoradiotherapy vs conventional radical surgery were compared.

The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.

A recent review article highlighted developments in the treatment of non-melanoma skin cancers, from new chemoprevention agents to telemedicine.

A new meta-analysis offers compelling evidence on the causal relationship between indoor tanning and skin cancer risk.

The findings of a systematic review may help standardize reflectance confocal microscopy terminology, which is used to describe non-melanocytic lesions.

Researchers studied whether the mechanistic target of mTORC2 directs UVB–induced apoptosis by regulating the expression of NOXA downstream of FOXO3a.

Cancer Network speaks with Dr. Ryan J. Sullivan about adjuvant therapies in development for melanoma patients.

A new study in Cancer Research evaluated the function of TRIM29 in regulating keratin distribution and migration/invasion of SCC.

Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.

A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma.

Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.

Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving avelumab monotherapy.